Efficacy of Combined Regional Inductive Moderate Hyperthermia and Chemotherapy in Patients With Multiple Liver Metastases From Breast Cancer

Klimanov, M. Yu.; Syvak, L.А.; Орел, В.Е.; Lavryk, G V; Tarasenko, T. Ye.; Orel, Valerii B.; Rykhalskyi, O.; Stegnii, Viadysiav V; Nesterenko, Andrii O

doi:10.1177/1533033818806003

Cited by 19 publications

(23 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regional inductive moderate hyperthermia in combination with chemotherapy can improve the therapeutic effect of breast cancer patients with multiple liver metastases. 57 The MegaTherm apparatus was set in the metastatic lesion to generate electromagnetic irradiation, with a temperature less than 40°C lasting for 30 minutes. The magnetic field generated during regional inductive moderate hyperthermia can significantly accelerate the interaction between chemical molecular oxygen and cellular metabolites, leading to remarkably enhanced oxidative stress in tumors and their microenvironments and increased apoptosis induced by hyperthermia.…”

Section: Hyperthermia Combined With Chemotherapymentioning

confidence: 99%

The Role of Hyperthermia in the Multidisciplinary Treatment of Malignant Tumors

Cheng

Weng

et al. 2019

Integr Cancer Ther

View full text Add to dashboard Cite

Hyperthermia is often used in combination with chemotherapy and radiotherapy for cancer treatment. Recently, immunotherapy has become a popular research area, breaking exciting new ground with concurrent immunotherapy and hyperthermia. Much evidence has demonstrated the effectiveness of multidisciplinary synergistic therapy, and the underlying mechanism has been gradually explored. In this review, we focus on the mechanism of various cancer treatments in the current literature and recent advances in hyperthermia. Additionally, we review clinical studies of hyperthermia combined with other therapies in the previous 10 years and propose future prospects for hyperthermia in multidisciplinary synergistic therapy.

show abstract

Section: Hyperthermia Combined With Chemotherapymentioning

confidence: 99%

The Role of Hyperthermia in the Multidisciplinary Treatment of Malignant Tumors

Cheng

Weng

et al. 2019

Integr Cancer Ther

View full text Add to dashboard Cite

show abstract

“…This HTA reports the available literature to show that there is wide evidence that HT associated with CHT, RT, and immunotherapy for advanced or recurrent breast cancer brings about improvements in both tumor response and OS that are maintained for a long time (up to 10 years). 36 - 44 …”

Section: Discussionmentioning

confidence: 99%

“…The HT in association with CHT is compared with CHT treatment alone in one study. 37 This combination improves the therapeutic efficacy in patients with metastatic breast cancer, resulting in a clinical benefit of 76% versus 42% of CHT alone ( P < .05). 37 …”

Section: Breast Cancermentioning

confidence: 95%

See 1 more Smart Citation

A Narrative Review of Regional Hyperthermia: Updates From 2010 to 2019

et al. 2020

View full text Add to dashboard Cite

The role of hyperthermia (HT) in cancer therapy and palliative care has been discussed for years in the literature. There are plenty of articles that show good feasibility of HT and its efficacy in terms of tumor response and survival improvements. Nevertheless, HT has never gained enough interest among oncologists to become a standard therapy in clinical practice. The main advantage of HT is the enhancement of chemotherapy (CHT), radiotherapy (RT), chemoradiotherapy (CRT), and immunotherapy benefits. This effect has been confirmed in several types of tumors: esophageal, gastrointestinal, pancreas, breast, cervix, head and neck, and bladder cancers, and soft tissue sarcoma. HT effects include oxygenation and perfusion changes, DNA repair inhibition and immune system activation as a consequence of new antigen exposure. The literature shows a wide variety of randomized, nonrandomized, and observational studies and both prospective and retrospective data to confirm the advantage of HT association to CHT and RT. There are still many ongoing trials on this subject. This article summarizes the available literature on HT in order to update the current knowledge on HT use in association with RT and/or CHT from 2010 up to 2019.

show abstract

“…This paper is a continuation of previous work designed to compare NACT versus NACT and RIMH in BC patients with multiple liver metastases. 17 The present study examines the application of RIMH to improve the antitumor efficacy of NACT followed by breast-conserving and reconstructive surgery in patients with locally advanced BC.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of Combination Neoadjuvant Chemotherapy and Regional Inductive Moderate Hyperthermia in the Treatment of Patients With Locally Advanced Breast Cancer

Loboda

Smolanka

Орел

et al. 2020

Technol Cancer Res Treat

Self Cite

View full text Add to dashboard Cite

Purpose: To evaluate the efficacy of neoadjuvant chemotherapy in combination with regional inductive moderate hyperthermia for patients with locally advanced breast cancer. Patients and Methods: 200 patients with stage IIB-IIIA breast cancer received neoadjuvant chemotherapy (control group, n = 97) or chemotherapy combined with hyperthermia (experimental group, n = 103). Inductive hyperthermia was set at 27.12 ± 0.16 MHz and the 50 W output power. Results: Thermal and color Doppler ultrasound imaging demonstrated that hyperthermia increased the surface temperature on the breasts to < 4°С while the mean values for systolic blood flow were 3.5 times as high as those prior to treatment. Assessment of tumor size and response found a (31.24 ± 3.85)% reduction in the size of the primary tumor in patients receiving chemotherapy + hyperthermia, while chemotherapy alone showed a (22.95 ± 3.61)% decrease on average (p = 0.034). The rate of objective response increased by 15.9% in the experimental group (р = 0.034) compared with the control group. The patients in the experimental group also had axillary lymph node regression of 14.17% greater than in the control group (p = 0.011). Moreover, the combination treatment allowed to increase the proportion of women eligible for breast-conserving and reconstructive surgery by 13.63% in the experimental group. The viable tumor volume was lower in patients receiving neoadjuvant chemotherapy + hyperthermia (24.4 ± 0.2)% compared with those given chemotherapy alone (30.4 ± 0.25)%. The 10-year overall survival rates were higher (log-rank: p = 0.009) in breast cancer patients who underwent chemotherapy combined with hyperthermia than in patients receiving chemotherapy only. Conclusion: The combination neoadjuvant chemotherapy and the technology of regional inductive moderate hyperthermia improved the efficacy of treatment for patients with locally advanced breast cancer staged IIB-IIIA.

show abstract

Efficacy of Combined Regional Inductive Moderate Hyperthermia and Chemotherapy in Patients With Multiple Liver Metastases From Breast Cancer

Cited by 19 publications

References 22 publications

The Role of Hyperthermia in the Multidisciplinary Treatment of Malignant Tumors

The Role of Hyperthermia in the Multidisciplinary Treatment of Malignant Tumors

A Narrative Review of Regional Hyperthermia: Updates From 2010 to 2019

Efficacy of Combination Neoadjuvant Chemotherapy and Regional Inductive Moderate Hyperthermia in the Treatment of Patients With Locally Advanced Breast Cancer

Contact Info

Product

Resources

About